14 Results for "

antithrombotic efficacy

" in MedChemExpress (MCE) Product Catalog:
Products (14)

14 Results for "antithrombotic efficacy" in MCE Product Catalog:

14
14 Cited Publications
Cat. No.: HY-111373
CAS No.: 1887095-82-0
Purity:  99.92%
Target:  

mTOR Autophagy

Research Areas:  

Cancer

RapaLink-1, the third-generation bivalent mTOR inhibitor, combines Rapamycin (HY-10219) with MLN0128 (HY-13328, a second-generation mTOR kinase inhibitor) by an inert chemical linker. RapaLink-1 shows better efficacy than Rapamycin or mTOR kinase inhibitors (TORKi), potently blocking cancer-derived, activating mutants of mTOR. RapaLink-1 can cross the blood-brain barrier. RapaLink-1 binding to FKBP12 results in targeted and durable inhibition of mTORC1. RapaLink-1 plays an antithrombotic role in antiphospholipid syndrome by improving autophagy. Anticancer activity .
loading...
    loading...
Cat. No.: HY-109122
CAS No.: 1159500-34-1
Purity:  99.75%
Synonyms: ACT-246475
Target:  

P2Y Receptor

Research Areas:  

Cardiovascular Disease

Selatogrel (ACT-246475) is a reversible and selective P2Y12 receptor antagonist which inhibits platelet aggregation with an IC50 of 8 nM. Selatogrel exhibits antithrombotic efficacy .
loading...
    loading...
Cat. No.: HY-122098
CAS No.: 481631-45-2
Purity:  99.87%
Synonyms: PAI-749
Target:  

PAI-1

Research Areas:  

Cardiovascular Disease

Diaplasinin (PAI-749) is a plasminogen activator inhibitor-1 (PAI-1) inhibitor with IC50 of 295 nM. Diaplasinin has antithrombotic efficacy .
loading...
    loading...
Cat. No.: HY-151196
CAS No.: 2816108-08-2
Target:  

Factor Xa

Research Areas:  

Cardiovascular Disease

FXIa-IN-10 (Compound 3f) is a potent activated factor XI (FXIa) inhibitor with an Ki of 0.17 nM. FXIa-IN-10 has good oral bioavailability .
loading...
    loading...
Cat. No.: HY-147079A
Purity:  92.75%
Synonyms: ARC 1779 sodium
Target:  

Integrin

Research Areas:  

Cardiovascular Disease

Egaptivon pegol sodium is an aptamer, which blocks binding of the von Willebrand Factor (VWF) to platelet GPIb receptors. Egaptivon pegol sodium has anti-thrombotic efficacy.
loading...
    loading...
Cat. No.: HY-147079
CAS No.: 934868-74-3
Synonyms: ARC 1779
Target:  

Integrin

Research Areas:  

Cardiovascular Disease

Egaptivon pegol (ARC1779) is an aptamer, which blocks binding of the von Willebrand Factor (VWF) to platelet GPIb receptors. Egaptivon pegol has anti-thrombotic efficacy.
loading...
    loading...
Cat. No.: HY-111755
CAS No.: 2299200-91-0
Target:  

P2Y Receptor

Research Areas:  

Cardiovascular Disease

P2Y12 antagonist 2 is a potent P2Y12 receptor antagonist. P2Y12 antagonist 2 exhibits excellent antiplatelet aggregation potency with an IC50 value of 2.94 μM as well as antithrombotic efficacy in a rat ferric chloride model. P2Y12 antagonist 2 shows a superior safety profile than Clopidogrel (HY-15283) in a rat tail-bleeding model. P2Y12 antagonist 2 can be used to research thromboembolic disorders .
loading...
    loading...
Cat. No.: HY-120491
CAS No.: 122841-09-2
Target:  

Thrombin

Research Areas:  

Cardiovascular Disease

L 722151 is a competitive inhibitor for factor XIIIa with Ki of 49 µM. L 722151 accelerates tissue plasminogen activator-catalyzed clot dissolution, and exhibits antithrombotic efficacy .
loading...
    loading...
Cat. No.: HY-123400A
CAS No.: 133276-52-5
Synonyms: iso-DTTX30; iso-DT-TX 30 SE
Research Areas:  

Cardiovascular Disease

Iso-Samixogrel (iso-DTTX30) is a combined thromboxane A2 receptor blocker and thromboxane synthetase inhibitor that exhibits potent antithrombotic activity. Iso-Samixogrel effectively eliminates recurrent arterial thrombus formation and inhibits collagen-induced platelet aggregation ex vivo. Iso-Samixogrel also prolongs sublingual bleeding time, demonstrating its biological efficacy in managing thrombosis.
loading...
    loading...
Cat. No.: HY-109122A
CAS No.: 2210298-04-5
Synonyms: ACT-246475 hydrochloride
Target:  

P2Y Receptor

Research Areas:  

Cardiovascular Disease

Selatogrel (ACT-246475) is a reversible and selective P2Y12 receptor antagonist which inhibits platelet aggregation with an IC50 of 8 nM. Selatogrel exhibits antithrombotic efficacy .
loading...
    loading...
Cat. No.: HY-109122R
CAS No.: 1159500-34-1
Synonyms: ACT-246475 (Standard)
Research Areas:  

Cardiovascular Disease

Selatogrel (Standard) is the analytical standard of Selatogrel (HY-109122). This product is intended for research and analytical applications. Selatogrel (ACT-246475) is a reversible and selective P2Y12 receptor antagonist which inhibits platelet aggregation with an IC50 of 8 nM. Selatogrel exhibits antithrombotic efficacy .
loading...
    loading...
Cat. No.: HY-P1711
CAS No.: 154447-41-3
Target:  

Peptides

Research Areas:  

Cardiovascular Disease

L 366763 is a potent peptide that acts as a fibrinogen receptor antagonist, preventing collagen-induced platelet aggregation and adhesion. L 366763 inhibits platelet deposition and maintains blood flow in a baboon thrombosis model, significantly prolonging bleeding time. L 366763 has antithrombotic efficacy, whereas recombinant LAPP does not have the same effect .
loading...
    loading...
Cat. No.: HY-19220
CAS No.: 167843-21-2
Target:  

Thrombin

Research Areas:  

Cardiovascular Disease

S-18326 is an orally active direct thrombin inhibitor. S-18326 inhibits thrombus formation by reversibly and with high affinity binding to the active site of thrombin, directly preventing the conversion of fibrinogen to fibrin. S-18326 effectively prolongs various clotting times in human plasma. S-18326 has demonstrated antithrombotic efficacy in multiple animal models without causing thrombocytopenia. S-18326 can be used in research on thromboembolic diseases .
loading...
    loading...
Cat. No.: HY-182012
Target:  

Drug Derivative

Research Areas:  

Cardiovascular Disease

DT-678 is an orally active antiplatelet and antithrombotic inhibitor. DT-678 is a conjugate formed by linking the active metabolite of Clopidogrel (HY-15283) with 3-nitropyridine-2-thiol via a mixed disulfide bond. DT-678 does not rely on CYP2C19 for activation, and directly releases active substances via thiol exchange reactions in vivo, exhibiting superior efficacy over Clopidogrel. DT-678 can be used in research related to acute coronary syndrome and thrombosis .
loading...
    loading...
  • 1